{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:35:30Z","timestamp":1781163330778,"version":"3.54.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Day One Biopharmaceuticals, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite high long-term survival rates, pediatric low-grade gliomas (pLGGs) are linked with significant tumor- and treatment-associated morbidities that may persist throughout life. The aims of this descriptive cross-sectional pilot study were to characterize health conditions among a cohort of patients with pLGG and explore the feasibility of quantifying disease burden and healthcare resource utilization (HRU).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Optum\u00ae Market Clarity Data were used to identify patients aged \u226418 years with an ICD-10 code for brain neoplasm, \u22651 physician notes, and with evidence of pLGG recorded between January 1, 2017 and June 30, 2018. Outcomes including health characteristics, HRU, medications, and procedures were assessed at 6-month intervals over 36 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred and fifty-four patients were identified with pLGG and over half experienced headache\/migraine, respiratory infection, pain, or behavioral issues during the 36-month study period. The most common comorbidities were ocular\/visual (including blindness), mental health disorders, seizures, and behavioral\/cognition disorders. Most symptoms and comorbidities persisted or increased during the study period, indicating long-term health deficits. HRU, including speciality care visits, filled prescriptions, and administered medications, was common; 74% of patients had prescriptions for anti-infectives, 56% antiemetics, and 52% required pain or fever relief. Sixty-five percent of patients underwent treatment to control their pLGG, the most common being brain surgery. Little decline was observed in medication use during the study period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with pLGG have complex healthcare needs requiring high HRU, often over a long time. Patients need to be optimally managed to minimize disease- and treatment-related burden and HRU.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npae037","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T08:18:14Z","timestamp":1714205894000},"page":"583-592","source":"Crossref","is-referenced-by-count":6,"title":["Disease burden and healthcare utilization in pediatric low-grade glioma: A United States retrospective study of linked claims and electronic health records"],"prefix":"10.1093","volume":"11","author":[{"given":"Susan","family":"Zelt","sequence":"first","affiliation":[{"name":"Day One Biopharmaceuticals, Inc. , Brisbane, California , USA (S.Z., T.C., S.Y., P.M., M.K., S.G.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabitha","family":"Cooney","sequence":"additional","affiliation":[{"name":"Day One Biopharmaceuticals, Inc. , Brisbane, California , USA (S.Z., T.C., S.Y., P.M., M.K., S.G.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandie","family":"Yu","sequence":"additional","affiliation":[{"name":"Day One Biopharmaceuticals, Inc. , Brisbane, California , USA (S.Z., T.C., S.Y., P.M., M.K., S.G.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailaja","family":"Daral","sequence":"additional","affiliation":[{"name":"Optum Lifesciences, Inc. , Eden Prairie, Minnesota, USA (S.D., B.K., R.M.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Krebs","sequence":"additional","affiliation":[{"name":"Optum Lifesciences, Inc. , Eden Prairie, Minnesota, USA (S.D., B.K., R.M.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riddhi","family":"Markan","sequence":"additional","affiliation":[{"name":"Optum Lifesciences, Inc. , Eden Prairie, Minnesota, USA (S.D., B.K., R.M.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Manley","sequence":"additional","affiliation":[{"name":"Day One Biopharmaceuticals, Inc. , Brisbane, California , USA (S.Z., T.C., S.Y., P.M., M.K., S.G.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kieran","sequence":"additional","affiliation":[{"name":"Day One Biopharmaceuticals, Inc. , Brisbane, California , USA (S.Z., T.C., S.Y., P.M., M.K., S.G.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandya","family":"Govinda Raju","sequence":"additional","affiliation":[{"name":"Day One Biopharmaceuticals, Inc. , Brisbane, California , USA (S.Z., T.C., S.Y., P.M., M.K., S.G.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"issue":"1","key":"2024091400032430500_CIT0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","article-title":"Pediatric low-grade glioma in the era of molecular diagnostics","volume":"8","author":"Ryall","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"Suppl 10","key":"2024091400032430500_CIT0002","doi-asserted-by":"crossref","first-page":"x1","DOI":"10.1093\/neuonc\/nou327","article-title":"Alex\u2019s Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007","volume":"16","author":"Ostrom","year":"2015","journal-title":"Neuro Oncol"},{"issue":"8","key":"2024091400032430500_CIT0003","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"4","key":"2024091400032430500_CIT0004","doi-asserted-by":"crossref","first-page":"e13060","DOI":"10.1111\/bpa.13060","article-title":"The 2021 WHO classification of tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors","volume":"32","author":"Bale","year":"2022","journal-title":"Brain Pathol."},{"issue":"Suppl 3","key":"2024091400032430500_CIT0005","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noac161","article-title":"CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024091400032430500_CIT0006","first-page":"vdaa094","article-title":"Long-term cognitive deficits in pediatric low-grade glioma (LGG) survivors reflect pretreatment conditions-report from the German LGG studies","volume":"2","author":"Traunwieser","year":"2020","journal-title":"Neurooncol Adv."},{"issue":"1","key":"2024091400032430500_CIT0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/MOP.0000000000000717","article-title":"Management of pediatric low-grade glioma","volume":"31","author":"de Blank","year":"2019","journal-title":"Curr Opin Pediatr."},{"issue":"13","key":"2024091400032430500_CIT0008","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jnci\/djp148","article-title":"Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study","volume":"101","author":"Armstrong","year":"2009","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"2024091400032430500_CIT0009","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/neuonc\/noq178","article-title":"Survival and long-term health and cognitive outcomes after low-grade glioma","volume":"13","author":"Armstrong","year":"2011","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024091400032430500_CIT0010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000533703","article-title":"A molecular update and review of current trials in paediatric low grade gliomas","volume":"58","author":"Al-Jilaihawi","year":"2023","journal-title":"Pediatr Neurosurg."},{"issue":"7","key":"2024091400032430500_CIT0011","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/cncr.31918","article-title":"Treatment burden and long-term health deficits of patients with low-grade gliomas or glioneuronal tumors diagnosed during the first year of life","volume":"125","author":"Liu","year":"2019","journal-title":"Cancer."},{"issue":"2","key":"2024091400032430500_CIT0012","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-022-03963-3","article-title":"Central nervous system tumors in children under 5 years of age: a report on treatment burden, survival and long-term outcomes","volume":"157","author":"Metzger","year":"2022","journal-title":"J Neurooncol."},{"issue":"17","key":"2024091400032430500_CIT0013","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1002\/cncr.32186","article-title":"Neuropsychological and socioeconomic outcomes in adult survivors of pediatric low-grade glioma","volume":"125","author":"Ris","year":"2019","journal-title":"Cancer."},{"issue":"11","key":"2024091400032430500_CIT0014","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1177\/0883073809342005","article-title":"Pediatric low-grade gliomas","volume":"24","author":"Sievert","year":"2009","journal-title":"J Child Neurol."},{"key":"2024091400032430500_CIT0015","doi-asserted-by":"crossref","first-page":"100857","DOI":"10.1016\/j.neo.2022.100857","article-title":"Pediatric low-grade glioma: targeted therapeutics and clinical trials in the molecular era","volume":"36","author":"Manoharan","year":"2023","journal-title":"Neoplasia"},{"issue":"3","key":"2024091400032430500_CIT0016","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3171\/2018.10.PEDS18377","article-title":"Childhood brain tumors: current management, biological insights, and future directions","volume":"23","author":"Pollack","year":"2019","journal-title":"J Neurosurg Pediatr"},{"issue":"6","key":"2024091400032430500_CIT0017","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1227\/NEU.0b013e318214a66e","article-title":"Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children\u2019s Oncology Group","volume":"68","author":"Wisoff","year":"2011","journal-title":"Neurosurgery."},{"issue":"22","key":"2024091400032430500_CIT0018","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1200\/JCO.2005.06.117","article-title":"Cognitive and adaptive outcome in low-grade pediatric cerebellar astrocytomas: evidence of diminished cognitive and adaptive functioning in National Collaborative Research Studies (CCG 9891\/POG 9130)","volume":"23","author":"Beebe","year":"2005","journal-title":"J Clin Oncol."},{"issue":"29","key":"2024091400032430500_CIT0019","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1200\/JCO.2008.17.1371","article-title":"Cognitive and adaptive outcome in extracerebellar low-grade brain tumors in children: a report from the Children\u2019s Oncology Group","volume":"26","author":"Ris","year":"2008","journal-title":"J Clin Oncol."},{"key":"2024091400032430500_CIT0020","doi-asserted-by":"crossref","first-page":"e2300017","DOI":"10.1200\/GO.23.00017","article-title":"Tackling pediatric low-grade gliomas: a global perspective","volume":"9","author":"Moreira","year":"2023","journal-title":"JCO Glob Oncol"},{"issue":"5","key":"2024091400032430500_CIT0021","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3390\/cancers12051152","article-title":"Pediatric low-grade gliomas","volume":"12","author":"Collins","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2024091400032430500_CIT0022","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","article-title":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u226416 years) low grade glioma","volume":"81","author":"Gnekow","year":"2017","journal-title":"Eur J Cancer."},{"issue":"2","key":"2024091400032430500_CIT0023","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/jpdn.2003.11","article-title":"Managing side effects of childhood cancer treatment","volume":"18","author":"Bryant","year":"2003","journal-title":"J Pediatr Nurs."},{"issue":"6","key":"2024091400032430500_CIT0024","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3390\/cancers14061540","article-title":"Short and long-term toxicity in pediatric cancer treatment: central nervous system damage","volume":"14","author":"Alessi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2024091400032430500_CIT0025","doi-asserted-by":"crossref","first-page":"AB160","DOI":"10.1016\/j.jaci.2019.12.421","article-title":"Immediate hypersensitivity reaction to chemotherapy in pediatric malignancies","volume":"145","author":"Mokkhamakkun","year":"2020","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"2024091400032430500_CIT0026","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma","volume":"41","author":"Bouffet","year":"2023","journal-title":"J Clin Oncol."},{"issue":"8","key":"2024091400032430500_CIT0027","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro Oncol"},{"issue":"22","key":"2024091400032430500_CIT0028","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1200\/JCO.2008.21.2738","article-title":"Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits","volume":"27","author":"Merchant","year":"2009","journal-title":"J Clin Oncol."},{"issue":"3","key":"2024091400032430500_CIT0029","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11060-014-1673-1","article-title":"Health related quality of life (HRQOL) in long-term survivors of pediatric low grade gliomas (LGGs)","volume":"121","author":"Nwachukwu","year":"2015","journal-title":"J Neurooncol."},{"issue":"11","key":"2024091400032430500_CIT0030","first-page":"e31915","article-title":"Predictors of seizure freedom in pediatric low-grade gliomas","volume":"14","author":"Budnick","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"2024091400032430500_CIT0031","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.semradonc.2015.02.009","article-title":"Clinical management of seizures in patients with low-grade glioma","volume":"25","author":"Piotrowski","year":"2015","journal-title":"Semin Radiat Oncol."},{"key":"2024091400032430500_CIT0032","doi-asserted-by":"crossref","first-page":"i57","DOI":"10.1093\/neuonc\/noad073.221","article-title":"[LGG-11] Cognitive, academic, and quality of life outcomes in survivors of pediatric low-grade glioma: challenging the \u2018benign tumor\u2019 perception [abstract]","volume":"25","author":"Nagabushan","year":"2023","journal-title":"Neuro Oncol"},{"issue":"8","key":"2024091400032430500_CIT0033","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamapediatrics.2023.2168","article-title":"Lifetime burden of psychological symptoms, disorders, and suicide due to cancer in childhood, adolescent, and young adult years: a systematic review and meta-analysis","volume":"177","author":"Lee","year":"2023","journal-title":"JAMA Pediatr"},{"key":"2024091400032430500_CIT0034","doi-asserted-by":"crossref","first-page":"100433","DOI":"10.1016\/j.lanepe.2022.100433","article-title":"Multimorbidity patterns and risk of hospitalisation in children: a population cohort study of 3.6 million children in England, with illustrative examples from childhood cancer survivors","volume":"20","author":"Chung","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"5","key":"2024091400032430500_CIT0035","doi-asserted-by":"crossref","first-page":"e1002296","DOI":"10.1371\/journal.pmed.1002296","article-title":"Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: a cohort study of 21,297 childhood cancer survivors","volume":"14","author":"de Fine Licht","year":"2017","journal-title":"PLoS Med."},{"issue":"5","key":"2024091400032430500_CIT0036","doi-asserted-by":"crossref","first-page":"e0232708","DOI":"10.1371\/journal.pone.0232708","article-title":"A detailed insight in the high risks of hospitalizations in long-term childhood cancer survivors","volume":"15","author":"Streefkerk","year":"2020","journal-title":"PLoS One."},{"issue":"23","key":"2024091400032430500_CIT0037","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.3390\/cancers14235982","article-title":"Comparison of neurocognitive functioning and fine motor skills in pediatric cancer survivors and healthy children","volume":"14","author":"Chipeeva","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024091400032430500_CIT0038","volume-title":"Guiding Cancer Control: A Path to Transformation","author":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Committee on a National Strategy for Cancer Control in the United States","year":"2019"},{"issue":"5","key":"2024091400032430500_CIT0039","doi-asserted-by":"crossref","first-page":"pkac059","DOI":"10.1093\/jncics\/pkac059","article-title":"Medication burden among pediatric cancer survivors: analysis of a population-wide electronic database in Hong Kong","volume":"6","author":"Ewig","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"2024091400032430500_CIT0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpeds.2017.11.063","article-title":"Early post-therapy prescription drug usage among childhood and adolescent cancer survivors","volume":"195","author":"Smitherman","year":"2018","journal-title":"J Pediatr."},{"issue":"3","key":"2024091400032430500_CIT0041","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(19)30800-9","article-title":"Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study","volume":"21","author":"Suh","year":"2020","journal-title":"Lancet Oncol."},{"key":"2024091400032430500_CIT0042","doi-asserted-by":"crossref","first-page":"i98","DOI":"10.1093\/neuonc\/noac079.358","article-title":"[LGG-46] survival of the fittest? A prognostic evaluation of paediatric low-grade glioma (PLGG) survivor functional outcomes [abstract]","volume":"24","author":"Green","year":"2022","journal-title":"Neuro Oncol"},{"issue":"6","key":"2024091400032430500_CIT0043","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.21873\/invivo.11735","article-title":"Prevalence of endocrine disorders in childhood brain tumor survivors in South Korea","volume":"33","author":"Heo","year":"2019","journal-title":"In Vivo"},{"issue":"2","key":"2024091400032430500_CIT0044","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phoj.2023.04.003","article-title":"Optic pathway and hypothalamic glioma, old problems, new paradigms","volume":"8","author":"Yaman Bajin","year":"2023","journal-title":"Pediatr Hematol Oncol J"},{"issue":"4","key":"2024091400032430500_CIT0045","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s43018-024-00733-0","article-title":"Temporal changes in treatment and late mortality and morbidity in adult survivors of childhood glioma: a report from the Childhood Cancer Survivor Study","volume":"5","author":"de Blank","year":"2024","journal-title":"Nat Cancer"},{"issue":"7","key":"2024091400032430500_CIT0046","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/pbc.24958","article-title":"Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database","volume":"61","author":"Bandopadhayay","year":"2014","journal-title":"Pediatr Blood Cancer."},{"issue":"2","key":"2024091400032430500_CIT0047","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.phoj.2023.04.004","article-title":"MAPK pathway-targeted therapies for pediatric low grade gliomas","volume":"8","author":"Lindsay","year":"2023","journal-title":"Pediatr Hematol Oncol J"},{"issue":"1","key":"2024091400032430500_CIT0048","first-page":"4","article-title":"Neuro-oncology practice clinical debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma","volume":"7","author":"Cooney","year":"2020","journal-title":"Neurooncol Pract."},{"issue":"9","key":"2024091400032430500_CIT0049","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S1470-2045(23)00320-0","article-title":"Financial hardship in families of children or adolescents with cancer: a systematic literature review","volume":"24","author":"Ritter","year":"2023","journal-title":"Lancet Oncol."},{"issue":"1","key":"2024091400032430500_CIT0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/1043454218810137","article-title":"A conceptual model of financial toxicity in pediatric oncology","volume":"36","author":"Santacroce","year":"2018","journal-title":"J Pediatr Oncol Nurs."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npae037\/58250103\/npae037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/11\/5\/583\/59116090\/npae037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/11\/5\/583\/59116090\/npae037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T08:33:07Z","timestamp":1726302787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/11\/5\/583\/7659104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,4,27]]},"published-print":{"date-parts":[[2024,9,13]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npae037","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,4,27]]}}}